Cargando…
Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis
BACKGROUND: The efficacy of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal cancer (LA-NPC) is controversial. In this paper, we conduct a meta-analysis based on relevant studies to provide strong evidence for clinical strategies....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921716/ https://www.ncbi.nlm.nih.gov/pubmed/33665166 http://dx.doi.org/10.3389/fonc.2020.610787 |
_version_ | 1783658524494004224 |
---|---|
author | Lai, Lin Chen, Xinyu Zhang, Chuxiao Chen, Xishan Chen, Li Tian, Ge Zhu, Xiaodong |
author_facet | Lai, Lin Chen, Xinyu Zhang, Chuxiao Chen, Xishan Chen, Li Tian, Ge Zhu, Xiaodong |
author_sort | Lai, Lin |
collection | PubMed |
description | BACKGROUND: The efficacy of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal cancer (LA-NPC) is controversial. In this paper, we conduct a meta-analysis based on relevant studies to provide strong evidence for clinical strategies. MATERIALS AND METHODS: We searched the MEDLINE, Embase, Cochrane, PubMed, and Web of Science databases for studies that stratified patients based on a high or low plasma Epstein–Barr virus deoxyribonucleic acid (EBV-DNA) load before treatment and compared the clinical efficacy of IC+CCRT vs. CCRT alone in LA-NPC. We tested for heterogeneity of studies and conducted sensitivity analysis. Subgroup analysis was performed for overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS). RESULTS: Seven studies with a total of 5289 cases were finally included in the meta-analysis. The heterogeneity test revealed the homogeneity of OS (I (2 )= 0.0%, p=0.794), PFS (I (2 )= 0.0%, p=0.778), DMFS (I (2 )= 0.0%, p=0.997), and LRFS (I (2 )= 0.0%, p=0.697) in patients with EBV-DNA loads of ≥4000 copies/ml in both the IC+CCRT and CCRT groups. The results reveal that IC+CCRT significantly extended the OS (HR 0.70 [95% CI 0.58-0.83], p=0.000), PFS (HR 0.83 [95% CI 0.70-0.99], p=0.033), and DMFS (HR 0.79 [95% CI 0.69-0.9], p=0.000) of patients compared with the CCRT group, but there were no beneficial effects on LRFS (HR 1.07 [95% CI 0.80-1.42], p=0.647). The heterogeneity test found that there was no significant heterogeneity of PFS (I (2 )= 0.0%, p=0.564), DMFS (I (2 )= 0.0%, p=0.648), LRFS (I (2 )= 22.3%, p=0.257), and OS (I (2 )= 44.6%, p=0.164) in patients with EBV-DNA loads of <4000 copies/ml. The results show that IC+CCRT prolonged DMFS (HR 0.57 [95% CI 0.39-0.85], p=0.006) of patients without significant improvements in OS (HR 0.88 [95% CI 0.55-1.26], p=0.240), PFS (HR 0.98 [95% CI 0.74-1.31], p=0.908), and LRFS (HR 0.98 [95% CI 0.54-1.77], p=0.943). CONCLUSIONS: Pretreatment plasma EBV-DNA can be considered a promising effective marker for the use of IC in LA-NPC patients. The addition of IC could improve the OS and PFS of patients with EBV-DNA load ≥4000 copies/ml, but we saw no efficacy in patients with EBV-DNA load <4000 copies/ml. Moreover, regardless of the EBV-DNA load, IC could improve DMFS, but there was no effect on LRFS. |
format | Online Article Text |
id | pubmed-7921716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79217162021-03-03 Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis Lai, Lin Chen, Xinyu Zhang, Chuxiao Chen, Xishan Chen, Li Tian, Ge Zhu, Xiaodong Front Oncol Oncology BACKGROUND: The efficacy of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal cancer (LA-NPC) is controversial. In this paper, we conduct a meta-analysis based on relevant studies to provide strong evidence for clinical strategies. MATERIALS AND METHODS: We searched the MEDLINE, Embase, Cochrane, PubMed, and Web of Science databases for studies that stratified patients based on a high or low plasma Epstein–Barr virus deoxyribonucleic acid (EBV-DNA) load before treatment and compared the clinical efficacy of IC+CCRT vs. CCRT alone in LA-NPC. We tested for heterogeneity of studies and conducted sensitivity analysis. Subgroup analysis was performed for overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS). RESULTS: Seven studies with a total of 5289 cases were finally included in the meta-analysis. The heterogeneity test revealed the homogeneity of OS (I (2 )= 0.0%, p=0.794), PFS (I (2 )= 0.0%, p=0.778), DMFS (I (2 )= 0.0%, p=0.997), and LRFS (I (2 )= 0.0%, p=0.697) in patients with EBV-DNA loads of ≥4000 copies/ml in both the IC+CCRT and CCRT groups. The results reveal that IC+CCRT significantly extended the OS (HR 0.70 [95% CI 0.58-0.83], p=0.000), PFS (HR 0.83 [95% CI 0.70-0.99], p=0.033), and DMFS (HR 0.79 [95% CI 0.69-0.9], p=0.000) of patients compared with the CCRT group, but there were no beneficial effects on LRFS (HR 1.07 [95% CI 0.80-1.42], p=0.647). The heterogeneity test found that there was no significant heterogeneity of PFS (I (2 )= 0.0%, p=0.564), DMFS (I (2 )= 0.0%, p=0.648), LRFS (I (2 )= 22.3%, p=0.257), and OS (I (2 )= 44.6%, p=0.164) in patients with EBV-DNA loads of <4000 copies/ml. The results show that IC+CCRT prolonged DMFS (HR 0.57 [95% CI 0.39-0.85], p=0.006) of patients without significant improvements in OS (HR 0.88 [95% CI 0.55-1.26], p=0.240), PFS (HR 0.98 [95% CI 0.74-1.31], p=0.908), and LRFS (HR 0.98 [95% CI 0.54-1.77], p=0.943). CONCLUSIONS: Pretreatment plasma EBV-DNA can be considered a promising effective marker for the use of IC in LA-NPC patients. The addition of IC could improve the OS and PFS of patients with EBV-DNA load ≥4000 copies/ml, but we saw no efficacy in patients with EBV-DNA load <4000 copies/ml. Moreover, regardless of the EBV-DNA load, IC could improve DMFS, but there was no effect on LRFS. Frontiers Media S.A. 2021-02-16 /pmc/articles/PMC7921716/ /pubmed/33665166 http://dx.doi.org/10.3389/fonc.2020.610787 Text en Copyright © 2021 Lai, Chen, Zhang, Chen, Chen, Tian and Zhu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Lai, Lin Chen, Xinyu Zhang, Chuxiao Chen, Xishan Chen, Li Tian, Ge Zhu, Xiaodong Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis |
title | Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis |
title_full | Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis |
title_fullStr | Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis |
title_full_unstemmed | Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis |
title_short | Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis |
title_sort | pretreatment plasma ebv-dna load guides induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer: a meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921716/ https://www.ncbi.nlm.nih.gov/pubmed/33665166 http://dx.doi.org/10.3389/fonc.2020.610787 |
work_keys_str_mv | AT lailin pretreatmentplasmaebvdnaloadguidesinductionchemotherapyfollowedbyconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcancerametaanalysis AT chenxinyu pretreatmentplasmaebvdnaloadguidesinductionchemotherapyfollowedbyconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcancerametaanalysis AT zhangchuxiao pretreatmentplasmaebvdnaloadguidesinductionchemotherapyfollowedbyconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcancerametaanalysis AT chenxishan pretreatmentplasmaebvdnaloadguidesinductionchemotherapyfollowedbyconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcancerametaanalysis AT chenli pretreatmentplasmaebvdnaloadguidesinductionchemotherapyfollowedbyconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcancerametaanalysis AT tiange pretreatmentplasmaebvdnaloadguidesinductionchemotherapyfollowedbyconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcancerametaanalysis AT zhuxiaodong pretreatmentplasmaebvdnaloadguidesinductionchemotherapyfollowedbyconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcancerametaanalysis |